Kratom is not a classical opioid, but its active compounds bind to the same brain receptors that opioids do. That makes the answer more nuanced than a simple yes or no. Kratom’s primary alkaloids activate mu-opioid receptors, producing pain relief, sedation, and a risk of dependence, yet its chemical structure, potency, and safety profile differ from drugs like morphine or fentanyl in important ways.
How Kratom Interacts With Opioid Receptors
The two alkaloids that matter most in kratom are mitragynine, which makes up the bulk of the plant’s active content, and 7-hydroxymitragynine, present in much smaller amounts but far more potent. Both bind to mu-opioid receptors, the same targets that morphine, codeine, and fentanyl act on. That receptor activity is the core reason kratom produces opioid-like effects: pain relief, relaxation, and euphoria at higher doses.
The key difference is how strongly they bind. Mitragynine’s binding affinity at the mu-opioid receptor is roughly 89 times weaker than morphine’s and about 90 times weaker than fentanyl’s. 7-hydroxymitragynine binds much more tightly, about 9 times stronger than mitragynine, and in lab preparations it has shown 13 times the potency of morphine. But 7-hydroxymitragynine typically represents only about 2% of kratom’s total alkaloid content, so most of what a kratom user consumes is the weaker compound.
Mitragynine also acts as a partial agonist at the mu-opioid receptor rather than a full agonist. Think of it like a dimmer switch instead of a light switch: it activates the receptor only partway, which creates a ceiling on how strong the effects can get. This partial activation appears to be one reason kratom carries a lower risk of fatal respiratory depression, the primary cause of death in opioid overdoses.
Why It Doesn’t Fit Neatly Into the “Opioid” Category
Classical opioids like morphine, oxycodone, and heroin share a phenanthrene chemical backbone. Kratom alkaloids have a completely different structure: they are indole alkaloids built on a monoterpene framework. Structurally, mitragynine looks more like compounds found in certain other tropical plants than it does like anything in a pharmacy’s opioid shelf. This structural difference matters because it changes how the compounds interact with the body’s signaling pathways downstream of the receptor.
One of the most clinically significant differences involves a signaling molecule called beta-arrestin. When traditional opioids activate mu-opioid receptors, they strongly recruit beta-arrestin, which is closely linked to respiratory depression and constipation. Kratom alkaloids recruit beta-arrestin only weakly. In animal studies, mitragynine produced no meaningful respiratory depression at doses many times higher than what humans typically take. At very high doses, a small, non-life-threatening decrease in breathing rate was observed, but it plateaued rather than continuing to worsen, consistent with a partial agonist’s ceiling effect.
What the FDA Says
The U.S. Food and Drug Administration treats kratom as a substance that acts on opioid receptors and can produce “classic opioid-related effects such as sedation, nausea/vomiting, constipation, physical dependence/withdrawal, and respiratory depression.” The agency has not approved kratom for any medical use. It considers kratom an adulterated ingredient when sold as a dietary supplement, food additive, or drug product, meaning it is not lawfully marketed in the U.S. in any of those forms.
Internationally, the World Health Organization’s Expert Committee on Drug Dependence reviewed kratom in 2021 and concluded there was insufficient evidence to recommend scheduling it as a controlled substance. As of 2024, kratom, mitragynine, and 7-hydroxymitragynine remain on the WHO’s surveillance list but have not been moved to a critical review.
Dose Makes the Difference
Kratom’s effects shift dramatically depending on how much you take. At low doses (roughly 1 to 5 grams of dried leaf), the dominant effects are stimulant-like: increased energy, alertness, and sociability. These effects have little in common with what people associate with opioids. At higher doses (5 to 15 grams), the opioid-like properties take over, producing sedation, pain relief, and euphoria. This dual nature is unusual and adds to the confusion about how to classify the substance.
Dependence and Withdrawal
Regular kratom use can lead to physical dependence, and stopping abruptly produces a withdrawal syndrome that closely resembles mild to moderate opioid withdrawal. In a study of regular users (people taking kratom more than four times per week, for an average of about 62 weeks), the most commonly reported withdrawal symptoms after stopping for a day or more included anxiety, irritability, restlessness, fatigue, low energy, gastrointestinal upset, body aches, difficulty sleeping, and cravings. Some also reported runny nose, watery eyes, hot and cold flashes, and restless legs.
About a third of people who met criteria for a kratom use disorder reported experiencing physical or psychological withdrawal when they stopped. The overall severity was generally described as mild to moderate, and tolerance and withdrawal were the most prominent features rather than the kind of severe psychosocial impairment often seen with stronger opioids. That said, dependence is real, and people who use kratom daily for weeks or months should expect some withdrawal discomfort if they stop suddenly.
Liver Injury Risk
A small but notable number of liver injury cases have been linked to kratom. In the largest case series from the U.S. Drug Induced Liver Injury Network, 11 cases were identified. The typical patient was a healthy male in his 40s who developed jaundice, itching, and abnormal liver tests after a median of about two weeks of kratom use. Eight of the 11 were hospitalized, but there were no fatalities, and most recovered after stopping kratom. The injury pattern was most often a mix of liver cell damage and bile flow disruption. While 11 cases is a small number relative to the millions of people who have used kratom, the short time to onset (5 to 28 days) and the consistency of the pattern suggest a real, if uncommon, risk.
Kratom as a Tool for Opioid Withdrawal
Many people who use kratom do so specifically to manage opioid withdrawal or transition off stronger opioids. Preclinical research supports the idea that mitragynine can reduce opioid withdrawal symptoms, and its partial agonist profile means it produces milder dependence and withdrawal of its own compared to full opioid agonists. Survey data from kratom users consistently reports that managing pain and opioid dependence are among the top reasons for use.
However, this use remains controversial and unregulated. Kratom itself can produce dependence, and there are no standardized doses, purity controls, or clinical guidelines for using it this way. Animal studies have shown that 14 days of daily mitragynine treatment can produce its own spontaneous withdrawal effects. For now, kratom’s potential as a formal treatment for opioid use disorder remains in the preclinical stage, with researchers noting it has “desirable characteristics” but needs considerably more study before it could be recommended in a clinical setting.
So Is It an Opioid?
It depends on how you define the word. If “opioid” means any substance that activates opioid receptors in the brain, then yes, kratom’s active compounds qualify. If “opioid” means a drug derived from or chemically similar to opium, then no. Kratom comes from a tropical tree in the coffee family, its alkaloids have a fundamentally different chemical structure from morphine or fentanyl, and its downstream signaling in the body diverges in ways that appear to reduce the most dangerous opioid risk: fatal respiratory depression. The most accurate description is that kratom contains compounds that are partial opioid receptor agonists with an atypical pharmacological profile, producing some but not all of the effects associated with classical opioids, generally at lower intensity.